Article Text


Therapeutic interventions in asthma and airways disease
P177 Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate in the treatment of asthma: a randomised controlled trial
  1. A Bodzenta-Lukaszyk1,
  2. A Dymek2,
  3. H Mansikka3
  1. 1Clinical Department of Allergology and Internal Diseases, Uniwersytet Medyczny w Białymstoku, Białystok, Poland
  2. 2Centrum Medyczne Lucyna Andrzej Dymek, Strzelce Opolskie, Poland
  3. 3Mundipharma Research Limited, Cambridge, UK


Introduction and Objectives A new asthma therapy combining fluticasone propionate and formoterol fumarate (FP/FORM) in a single pressurised metered dose inhaler has been developed. The efficacy and safety of FP/FORM and fluticasone propionate/salmeterol xinafoate (FP/SAL) therapy were compared.

Methods Adults (N=202) with mild to moderate-severe asthma were randomised 1:1 to 12 weeks of treatment with FP/FORM (100/10 μg or 250/10 μg) or FP/SAL (100/50 μg or 250/50 μg), both twice daily, in an open-label, parallel-group, multicentre study. The starting dose was based on the dose of inhaled corticosteroid the patient received before the study. Lung function and safety assessments were made during the 12-week period. The primary endpoint was mean morning pre-dose FEV1 at Week 12.

Results FP/FORM was as effective as FP/SAL, with a least squares (LS) mean difference in morning pre-dose FEV1 at Week 12 of –0.061 L between treatments. Non-inferiority of FP/FORM to FP/SAL was demonstrated (the lower limit of the 95% CI exceeded the acceptance limit of –0.2 L). Pre-dose FEV1 increased in both groups from baseline to Week 12 (FP/FORM: +0.196 L; FP/SAL: +0.257 L). The LS mean difference in change in pre-dose FEV1 was –0.061 L between treatments (95% CI –0.161 to 0.040). Non-inferiority of FP/FORM to FP/SAL was demonstrated (the lower limit of the 95% CI exceeded the acceptance limit of –0.2 L). In total, 72.3% (73/101) patients started on FP/FORM 250/10 μg and 75.2% (76/101) on FP/SAL 250/50 μg. Eight patients (FP/FORM: n=5; FP/SAL: n=3) required an increase in dose. Similar numbers of patients treated with FP/FORM and FP/SAL discontinued due to lack of efficacy (FP/FORM: n=1; FP/SAL: n=2). Twenty-three patients (11.4%) experienced mild or moderate asthma exacerbations. Four patients (2.0%) experienced severe exacerbations (FP/FORM: n=3; FP/SAL: n=1; p=0.621). Overall, 23.8% of patients experienced at least one AE. The rate was the same in both treatment groups (24/101). Most AEs were mild or moderate. No clinically important changes in laboratory results, vital signs or ECGs were observed.

Conclusion FP/FORM and FP/SAL had similar efficacy and safety profiles.

Abstract P177 Table 1

Pre-dose FEV1 at Week 12–per protocol set

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.